BB114814 inhibitors are a class of chemical compounds designed to specifically inhibit the activity of the protein BB114814, a protein implicated in various intracellular signaling pathways. BB114814 is known for its role in regulating several key cellular functions, including signal transduction, gene expression, and protein modification processes. By inhibiting the activity of BB114814, these compounds interfere with the normal signaling dynamics within the cell, affecting downstream effects such as protein phosphorylation and gene transcription. This can result in significant changes in cellular behavior, particularly in response to external stimuli that typically trigger these signaling pathways. BB114814 inhibitors are therefore valuable tools for probing the functional significance of this protein in cellular biology and for understanding the mechanisms that govern its regulatory role.
The chemical structures of BB114814 inhibitors are typically designed to interact with the active site or other critical domains of the BB114814 protein, disrupting its ability to participate in molecular interactions and enzymatic activities. The development of these inhibitors often involves extensive structure-activity relationship (SAR) studies to optimize the binding affinity, selectivity, and potency of the compounds. These inhibitors are used in biochemical research to explore the specific signaling pathways influenced by BB114814 and to elucidate its role in cellular processes such as proliferation, differentiation, and stress response. Through these studies, BB114814 inhibitors contribute to a deeper understanding of intracellular signaling networks and their regulation, offering insight into the molecular frameworks that support cellular function and adaptation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits CUB domain containing protein 3 by targeting protein tyrosine kinases which are upstream regulators, thereby preventing phosphorylation events that are necessary for the protein's functional activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits Src family kinases which are implicated in the activation process of CUB domain containing protein 3, thereby inhibiting its function. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib inhibits receptor tyrosine kinases that could be upstream of CUB domain containing protein 3, inhibiting its functional activity. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits epidermal growth factor receptor (EGFR) kinase activity, potentially reducing the activation of pathways that involve CUB domain containing protein 3, leading to its inhibition. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib inhibits ErbB2 and EGFR, which may be involved in the signaling pathways that regulate CUB domain containing protein 3 activity, thus inhibiting it. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits multiple tyrosine protein kinases, potentially reducing signaling through pathways that involve CUB domain containing protein 3, thereby inhibiting its function. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib inhibits vascular endothelial growth factor receptor (VEGFR) which could be involved in pathways that activate CUB domain containing protein 3, and thereby inhibit its activity. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib selectively inhibits RET kinase, VEGFR, and EGFR, which could be part of the signaling network involving CUB domain containing protein 3, resulting in its inhibition. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib selectively inhibits EGFR tyrosine kinase, potentially disrupting signaling pathways that CUB domain containing protein 3 may be involved in, leading to its inhibition. | ||||||